



**California State Board of Pharmacy**

1625 N. Market Blvd, N219, Sacramento, CA 95834

Phone: (916) 574-7900

Fax: (916) 574-8618

www.pharmacy.ca.gov

STATE AND CONSUMER SERVICES AGENCY

DEPARTMENT OF CONSUMER AFFAIRS

GOVERNOR EDMUND G. BROWN JR.

## **Communication and Public Education Committee Report**

Ryan Brooks, Chair, Public Member  
Shirley Wheat, Board Member  
Ramon Castellblanch, PhD, Board Member  
Debbie Veale, RPh, Board Member  
Rosalyn Hackworth, Board Member

---

**There has been no meeting of the Communications and Public Education Committee this quarter.**

**a. FOR INFORMATION: Update of the State's Emergency Contraception Protocol Regulation (16 California Code of Regulations Section 1746) and Consumer Fact Sheet**

**Attachment 1**

The Board of Pharmacy has begun work to update the emergency contraception protocol authorized by California Business and Professions Code section 4052.3 and 16 California Code of Regulations section 1746. These sections authorize a pharmacist to initiate emergency contraception pursuant to a state protocol developed by the Medical Board of California and the Board of Pharmacy, and with the assistance of the American College of Obstetricians and Gynecologists, the California Pharmacists Association and other entities.

The current state protocol was developed by the Medical Board in 2004 and then later adopted by this board as a regulation. Since the time of adoption, there have been changes in the availability of emergency contraception medicine, the manufacturers who produce the medication, and there is a typo that needs correction (mcg instead of mg).

Since the May Board Meeting, the executive officer has completed edits into a revised protocol from CPhA's representative (a women's health specialist pharmacist), and two representatives of the American College of Obstetricians and Gynecologists. This revised protocol has been submitted to the Medical Board of California, which must approve the modified protocol. This review will occur at the July 29 meeting of that board.

Next, the Board of Pharmacy will need to proceed with a rulemaking to update the requirements as a regulation. As a final part of the rulemaking, this board will need to update the patient information fact sheet, which is required to be provided to patients by the pharmacists using the protocol to dispense emergency contraception. For your review, a copy of these documents appears as **Attachment 1**.

**b. FOR INFORMATION: Update on Public Outreach Activities**

A travel freeze was implemented in May pursuant to the Governor's executive order, suspending travel for all but the most essential and mandated purposes. In accordance with this mandate, the board reduced its public appearances. Nevertheless, the board was able to provide the following presentations, some of which were scheduled before the executive order.

Public and licensee outreach activities performed during the fourth quarter of Fiscal Year 10/11 include:

- April 27, 2011 – Executive Officer Herold provides an update on board activities to senior executive members of the Healthcare Distribution Management Association in a Sacramento meeting.
- May 5, 2011 – Supervising Inspector Dang provides a CE presentation on new pharmacy laws to over 70 pharmacists at an association meeting in Los Angeles.
- May 11, 2011 – Executive Officer Herold provides a presentation on California's patient-centered labeling requirements to over 100 individuals at the annual Ralphs manager meeting in Orange County.
- May 21, 2011 – Executive Officer Herold provides a presentation to over 100 attendees on the board's citation and fine and enforcement programs at the CPhA Celebrate Pharmacy Conference in Oakland. Board Inspector Hunt provides a presentation on responsibilities on how to survive a board inspection and the roles of a PIC at the same conference. New Supervising Inspector Young also provides a presentation on addressing prescription drug abuse.
- June 1, 2011 – Executive Officer Herold participates in the mandatory DCA day-long training for new board members in Los Angeles on the roles of the executive officer, roles of a board member, and the components of the state enforcement, legislative and budget programs in operation at the boards.
- June 2, 2011 – Executive Officer Herold provides a Webinar-like presentation at an Axway conference in New Jersey on California's e-pedigree requirements.
- June 28, 2011 – Executive Officer Herold participates in a conference call of western states' pharmacy board directors hosted by the NAPB. This call was initiated at Ms. Herold's request to allow discussion of regulatory issues involving neighboring states.

- June 29, 2011 – Executive Officer Herold tapes a “postscript blog” with Community Catalyst in Washington DC on the security of the pharmaceutical supply chain and the issues identified in California surrounding the 2008 heparin recalls. This is part of the PEW Trust’s forthcoming report on the 2008 heparin contamination which affected the supply of heparin in the US.

c. **FOR INFORMATION: Fourth Quarterly Report on Committee Goals for 2010/11**  
**Attachment 2**

**Attachment 2** contains a copy of the fourth quarter’s strategic plan update Committee Goals.

## **Pharmacists Protocol for Dispensing Emergency Contraception**

Pharmacists may furnish emergency contraception medications based on a statewide protocol adopted by the California State Board of Pharmacy and the Medical Board of California (section 4052.3(a)(2) of the California Business and Professions Code).

On the following page is the approved protocol. Pharmacists may use this protocol after they have completed one hour of continuing education credit in emergency contraception .

Additionally pharmacists may furnish emergency contraception medications to patients based on a protocol with a single licensed prescriber (section 4052.3 of the California Business and Professions Code).

Pharmacists may also furnish levonorgestrel emergency contraception without a prescription or a physician protocol to a man or woman aged 17 or older pursuant to FDA requirements.

This statewide protocol was prepared with the intent to keep it simple and to comply with the statutory requirements established by California law.

## **Protocol for Pharmacists Furnishing Emergency Contraception (EC)**

**Authority: Section 4052.3(a)(2) of the California Business and Professions Code authorizes a pharmacist to furnish emergency contraception pursuant to a protocol approved by the California State Board of Pharmacy and the Medical Board of California. Use of the following protocol satisfies that requirement.**

Purpose: To provide timely access to emergency contraceptive medication and ensure that the patient receives adequate information to successfully complete therapy.

Procedure: When a patient requests emergency contraception, the pharmacist will ask and communicate the following:

- Are you allergic to any medications?
- Timing is an essential element of the product's effectiveness. EC should be taken as soon as possible after unprotected intercourse. Treatment may be initiated up to five days (120 hours) after unprotected intercourse.
- EC use will not interfere with an established or implanted pregnancy.
- If more than 72 hours have elapsed since unprotected intercourse, the use of ella® (ulipristal) may be more effective than levonorgestrel. Other options for EC include consultation with your physician regarding insertion of an IUD.

The pharmacist shall provide a fact sheet and review any questions the patient may have regarding EC. In addition, the pharmacist shall collect the information required for a patient medication record by Section 1707.1 of Title 16 of the California Code of Regulations (reference attached).

Fact Sheet: The pharmacist will provide the patient with a copy of the current EC fact sheet approved by the Board of Pharmacy.

Referrals and Supplies: If emergency contraception services are not immediately available at the pharmacy or the pharmacist declines to furnish pursuant to conscience clause, the pharmacist will refer the patient to another emergency contraception provider. The pharmacist shall comply with all state mandatory reporting laws, including sexual abuse laws.

The pharmacist may provide up to 12 non-spermicidal condoms to each Medi-Cal and Family PACT client who obtains emergency contraception.

Advanced Provision: The pharmacist may dispense emergency contraception medication for a patient in advance of the need for emergency contraception.

EC Product Selection: The pharmacist will provide emergency contraception medication from the list of products appended to this protocol. This list must be kept current and maintained in the pharmacy. Along with emergency contraception products, the list will include adjunctive medications indicated for nausea and vomiting associated with taking EC containing estrogen. Patients will be provided information concerning dosing and potential adverse effects.

Documentation: Each prescription authorized by a pharmacist will be documented in a patient profile as required by law.

Training: Prior to furnishing emergency contraception, pharmacists who participate in this protocol must have completed a minimum of one hour of continuing education specific to emergency contraception.

Appendix 1: Medications Used for Emergency Contraception

| <b>Dedicated Approved Products for Emergency Contraception</b> |  |  |                                  |                             |
|--|--|--|----------------------------------|-----------------------------|
| Brand  |  | Dose   | Ethinyl Estradiol per dose (mcg) |                             |
| <b>One Dose Regimen</b>  |  |  |                                  |                             |
|  |  |  |                                  |                             |
| PlanB-OneStep  |  | 1 tablet                                     | 0                                | 1.5mg levonorgestrel        |
| Ella   |  | 1 tablet                                     | 0                                | 30mg ulipristal             |
| <b>Two Dose Regimen</b>  |  |  |                                  |                             |
| NextChoice   |  | 1 tablet per dose                            | 0                                | 1.5mg levonorgestrel        |
|  |  |  |                                  |                             |
|  |  |  |                                  |                             |
| <b>Oral Contraceptive Pills</b>                                |  |  |                                  |                             |
| Brand  |  | Tablets per Dose (two doses 12 hours apart*) | Ethinyl Estradiol per dose(mcg)  | Levonorgestrel per dose(mg) |
| Levora   |  | 4 white tablets                              | 120                              | 0.6                         |
| Ovral  |  | 2 white tablets                              | 100                              | 0.5                         |
| Ogestrel   |  | 2 white tablets                              | 100                              | 0.5                         |
| Nordette   |  | 4 light-orange tablets                       | 120                              | 0.6                         |
| Tri-Levlen   |  | 4 yellow tablets                             | 100                              | 0.5                         |
| Alesse   |  | 5 pink tablets                               | 100                              | 0.5                         |
| Aviane   |  | 5 orange tablets                             | 100                              | 0.5                         |
| Triphasil  |  | 4 yellow tablets                             | 120                              | 0.5                         |
| Levlen   |  | 4 light-orange tablets                       | 120                              | 0.6                         |
| Trivora  |  | 4 pink tablets                               | 120                              | 0.5                         |
| Levlite  |  | 5 pink tablets                               | 100                              | 0.5                         |
| Lo/Ovral   |  | 4 white tablets                              | 120                              | 0.5                         |
| Low-Ogestrel   |  | 4 white tablets                              | 120                              | 0.6                         |
| Ovrette  |  | 20 yellow tablets                            | 0                                | 0.75                        |

\*The progestin in Ovral, Lo/Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each dose is twice the amount of levonorgestrel

\*\* In addition to the products listed above, generic equivalent products may be furnished. Estrogen containing regimens are not preferred and should be used only when the other options are not available

**Appendix 2 -- ~~Sample list~~ List of Anti-Emetics for Use with Emergency Contraception.**

**Anti-nausea Treatment Options for use with Emergency Contraception**

| <b>Drug</b>                                       | <b>Dose</b>   | <b>Timing of Administration</b>  |
|---|---|--|
| <b>Non-prescription Drugs</b>                     |   |  |
| Meclizine hydrochloride<br>(Dramamine II, Bonine) | One or two 25 mg tablets                            | 1 hour before first EC dose;<br>repeat if needed in 24 hours                       |
| Diphenhydramine<br>hydrochloride (Benadryl)       | One or two 25 mg tablets or<br>capsules.            | 1 hour before first EC dose;<br>repeat as needed every 4-6<br>hours                |
| Dimenhydrinate<br>(Dramamine)                     | One or two 50 mg tablets or<br>4-8 teaspoons liquid | 30 minutes to 1 hour before<br>first ECP dose; repeat as<br>needed every 4-6 hours |
| Cyclizine hydrochloride<br>(Marezine)             | One 50 mg tablet                                    | 30 minutes before first EC<br>dose;<br>repeat as needed every 4-6<br>hours         |

**Appendix 3 – Title 16, Section 1707.1 of the California Code of Regulations**

**§1707.1. Duty to Maintain Medication Profiles (Patient Medication Records).**

(a) A pharmacy shall maintain medication profiles on all patients who have prescriptions filled in that pharmacy except when the pharmacist has reasonable belief that the patient will not continue to obtain prescription medications from that pharmacy.

(1) A patient medication record shall be maintained in an automated data processing or manual record mode such that the following information is readily retrievable during the pharmacy's normal operating hours.

(A) The patient's full name and address, telephone number, date of birth (or age) and gender;

(B) For each prescription dispensed by the pharmacy:

1. The name, strength, dosage form, route of administration, if other than oral, quantity and directions for use of any drug dispensed;

2. The prescriber's name and where appropriate, license number, DEA registration number or other unique identifier;

3. The date on which a drug was dispensed or refilled;

4. The prescription number for each prescription; and

5. The information required by section 1717.

(C) Any of the following which may relate to drug therapy: patient allergies, idiosyncrasies, current medications and relevant prior medications including nonprescription medications and relevant devices, or medical conditions which are communicated by the patient or the patient's agent.

(D) Any other information which the pharmacist, in his or her professional judgment, deems appropriate.

(2) The patient medication record shall be maintained for at least one year from the date when the last prescription was filled.

Authority cited: Sections 4005, 4121 and 4122, of the Business and Professions Code.

Reference: Sections 4005, 4121 and 4122, of the Business and Professions Code.

## Pharmacists Protocol for Dispensing Emergency Contraception

Pharmacists may furnish emergency contraception medications based on a statewide protocol adopted by the California State Board of Pharmacy and the Medical Board of California (section 4052.3(a)(2) of the California Business and Professions Code).

On the following page is the approved protocol. Pharmacists may use this protocol after they have completed one hour of continuing education credit in emergency contraception.

Additionally pharmacists may furnish emergency contraception medications to patients based on a protocol with a single licensed prescriber (section 4052.3 of the California Business and Professions Code).

Pharmacists may also furnish [levonorgestrel](#) emergency contraception without a prescription or a physician protocol to a man or woman aged 17 or older pursuant to FDA requirements.

This statewide protocol was prepared with the intent to keep it simple and to comply with the statutory requirements established by California law.

Deleted: ¶  
Senate Bill 490 (Chapter 651, Statutes of 2003) permits pharmacists

Formatted: Strikethrough

Deleted:

Deleted:

Formatted: No underline

Deleted: ¶

Formatted: Strikethrough

Deleted: (a requirement of the new law)

Deleted: Prior legislation (Senate Bill 1169, Chapter 900, Statutes of 2001) P

Formatted: No underline

Deleted: also permits pharmacists to

Deleted: Existing protocols developed with a prescriber remain valid.

Deleted: Last p

Formatted: No underline

Deleted: also

Deleted:

Deleted: Plan B

Deleted:

Deleted: r

Deleted: The

Formatted: No underline

Deleted:

Deleted: Senate Bill 490.

Deleted: The statutory provisions for pharmacists furnishing emergency contraception are found in California Business and Professions Code section 4052.¶

Formatted: Strikethrough

## Protocol for Pharmacists Furnishing Emergency Contraception (EC)

**Authority:** Section 4052.3(a)(2) of the California Business and Professions Code authorizes a pharmacist to furnish emergency contraception pursuant to a protocol approved by the California State Board of Pharmacy and the Medical Board of California. Use of the following protocol satisfies that requirement.

**Purpose:** To provide timely access to emergency contraceptive medication and ensure that the patient receives adequate information to successfully complete therapy.

Deleted: within required limits

Deleted: ¶

**Procedure:** When a patient requests emergency contraception, the pharmacist will ask and communicate the following:

- Are you allergic to any medications?
- Timing is an essential element of the product's effectiveness. EC should be taken as soon as possible after unprotected intercourse. Treatment may be initiated up to five days (120 hours) after unprotected intercourse.
- EC use will not interfere with an established or implanted pregnancy.
- If more than 72 hours have elapsed since unprotected intercourse, the use of ella® (ulipristal) may be more effective than levonorgestrel. Other options for EC include consultation with your physician regarding insertion of an IUD.

Deleted: state¶

Formatted: Strikethrough

Formatted: Indent: Left: 0.5"

Deleted: ¶

Deleted: ¶

Deleted: ¶

Formatted: No underline

Deleted: EC effectiveness declines gradually over five days and

Formatted: Space After: 0 pt, Line spacing: single

Deleted: (

Deleted: )

Formatted: Space After: 0 pt

Deleted:

Deleted: her

Deleted: the

Deleted: I

The pharmacist shall provide a fact sheet and review any questions the patient may have regarding EC. In addition, the pharmacist shall collect the information required for a patient medication record by Section 1707.1 of Title 16 of the California Code of Regulations (reference attached).

**Fact Sheet:** The pharmacist will provide the patient with a copy of the current EC fact sheet approved by the Board of Pharmacy.

**Referrals and Supplies:** If emergency contraception services are not immediately available at the pharmacy or the pharmacist declines to furnish pursuant to conscience clause, the pharmacist will refer the patient to another emergency contraception provider. The pharmacist shall comply with all state mandatory reporting laws, including sexual abuse laws.

The pharmacist may provide up to 12 non-spermicidal condoms to each Medi-Cal and Family PACT client who obtains emergency contraception.

**Advanced Provision:** The pharmacist may dispense emergency contraception medication for a patient in advance of the need for emergency contraception.

**EC Product Selection:** The pharmacist will provide emergency contraception medication from the list of products appended to this protocol. This list must be kept current and maintained in the pharmacy. Along with emergency contraception products, the list will include adjunctive medications indicated for nausea and vomiting associated with taking EC containing estrogen. Patients will be provided information concerning dosing and potential adverse effects.

Deleted: compatible with product information

Deleted: p

Deleted: .

Documentation: Each prescription authorized by a pharmacist will be documented in a patient profile as required by law.

Training: Prior to furnishing emergency contraception, pharmacists who participate in this protocol must have completed a minimum of one hour of continuing education specific to emergency contraception.

**Deleted:** or curriculum-based instruction from an ACPE accredited School of Pharmacy

**Deleted:** ¶

**Formatted:** Font: Calibri, 11 pt

**Formatted:** Font color: Black

**Formatted:** Font: Calibri, 11 pt

Appendix 1: Medications Used for Emergency Contraception

Deleted: Brands and Doses of Oral Contraceptive Tablets

| Dedicated Approved Products for Emergency Contraception |  |  |                                  |                             |
|---|--|--|----------------------------------|-----------------------------|
| Brand   |  | Dose   | Ethinyl Estradiol per dose (mcg) |                             |
| <b>One Dose Regimen</b>                                 |  |  |                                  |                             |
| <a href="#">PlanB-OneStep</a>                           |  | 1 tablet                                     | 0                                | 1.5mg levonorgestrel        |
| <a href="#">Ella</a>                                    |  | 1 tablet                                     | 0                                | 30mg ulipristal             |
| <b>Two Dose Regimen</b>                                 |  |  |                                  |                             |
| <a href="#">NextChoice</a>                              |  | 1 tablet per dose                            | 0                                | 1.5mg levonorgestrel        |
|   |  |  |                                  |                             |
|   |  |  |                                  |                             |
| <b>Oral Contraceptive Pills</b>                         |  |  |                                  |                             |
| Brand   |  | Tablets per Dose (two doses 12 hours apart*) | Ethinyl Estradiol per dose(mcg)  | Levonorgestrel per dose(mg) |
| Levora  |  | 4 white tablets                              | 120                              | 0.6                         |
| Ovral   |  | 2 white tablets                              | 100                              | 0.5                         |
| Ogestrel  |  | 2 white tablets                              | 100                              | 0.5                         |
| Nordette  |  | 4 light-orange tablets                       | 120                              | 0.6                         |
| Tri-Levlen  |  | 4 yellow tablets                             | 100                              | 0.5                         |
| Alesse  |  | 5 pink tablets                               | 100                              | 0.5                         |
| Aviane  |  | 5 orange tablets                             | 100                              | 0.5                         |
| Triphasil   |  | 4 yellow tablets                             | 120                              | 0.5                         |
| Levlen  |  | 4 light-orange tablets                       | 120                              | 0.6                         |
| Trivora   |  | 4 pink tablets                               | 120                              | 0.5                         |
| Levlite   |  | 5 pink tablets                               | 100                              | 0.5                         |
| Lo/Ovral  |  | 4 white tablets                              | 120                              | 0.5                         |
| Low-Ogestrel  |  | 4 white tablets                              | 120                              | 0.6                         |
| Ovrette   |  | 20 yellow tablets                            | 0                                | 0.75                        |

- Deleted: Manufacturer
- Deleted: Tablets per
- Deleted: Levonorgestrel per dose(mg)
- Deleted: PlanB
- Deleted: Duramed
- Deleted: 2 tablets per dose
- Deleted: 0
- Deleted: 1.5
- Deleted: Plan B
- Deleted: Duramed
- Deleted: 1 tablet per dose
- Deleted: 0
- Deleted: 0.75
- Deleted: Preven\*\*
- Deleted: Duramed
- Deleted: 2 tablets per dose
- Deleted: 100
- Deleted: 0.50
- Deleted: Manufacturer
- Deleted: Watson
- Deleted: Wyeth
- Deleted: Watson
- Deleted: Wyeth
- Deleted: Berlex
- Deleted: Wyeth
- Deleted: Duramed
- Deleted: Wyeth
- Deleted: Berlex
- Deleted: Watson
- Deleted: Berlex
- Deleted: Wyeth
- Deleted: Wyeth

\*The progestin in Ovral, Lo/Ovral, and Ovrette is norgestrel, which contains two isomers, only one of which (levonorgestrel) is bioactive; the amount of norgestrel in each dose is twice the amount of levonorgestrel

\*\* [In addition to the products listed above, generic equivalent products may be furnished. Estrogen containing regimens are not preferred and should be used only when the other options are not available.](#)


- Deleted: \*\*
- Formatted: Font: Times New Roman, 12 pt
- Formatted: Font: Times New Roman, 12 pt
- Deleted: Preven was discontinued (... [1])
- Formatted: Font: Times New Roman
- Formatted (... [2])

~~Appendix 2 --Sample list~~ **List of Anti-Emetics for Use with Emergency Contraception.**

**Formatted:** Font: CEHKCB+ TimesNewRoman,Bold, Font color: Black, Strikethrough

## Anti-nausea Treatment Options for use with Emergency Contraception

| Drug  | Dose   | Timing of Administration   |
|---|--|--|
| <b>Non-prescription Drugs</b><br>Meclizine hydrochloride (Dramamine II, Bonine) | One or two 25 mg tablets                         | 1 hour before first EC dose; repeat if needed in 24 hours                    |
| Diphenhydramine hydrochloride (Benadryl)  | One or two 25 mg tablets or capsules.            | 1 hour before first EC dose; repeat as needed every 4-6 hours                |
| Dimenhydrinate (Dramamine)  | One or two 50 mg tablets or 4-8 teaspoons liquid | 30 minutes to 1 hour before first ECP dose; repeat as needed every 4-6 hours |
| Cyclizine hydrochloride (Marezine)  | One 50 mg tablet                                 | 30 minutes before first EC dose; repeat as needed every 4-6 hours            |



~~Deleted: ¶ Appendix 2 --Sample list of Anti-Emetics for Use with Emergency Contraception.~~

~~Deleted: Anti-nausea Treatment Options for use with Emergency Contraception~~

~~Deleted: Drug~~

~~Deleted: Dose~~

~~Deleted: Timing of Administration~~

~~Deleted: Non-prescription Drugs~~

~~Deleted: One or two 25 mg tablets~~

~~Deleted: Meclizine hydrochloride (Dramamine II, Bonine)~~

~~Deleted: 1 hour before first EC dose; repeat if needed in 24 hours~~

~~Deleted: Diphenhydramine~~

~~Deleted: One or two 25 mg tablets or~~

~~Deleted: 1 hour before first EC dose;~~

~~Deleted: hydrochloride (Benadryl)~~

~~Deleted: capsules.~~

~~Deleted: repeat as needed every 4-6 hours~~

~~Deleted: Dimenhydrinate (Dramamine)~~

~~Deleted: One or two 50 mg tablets or 4-8 teaspoons liquid~~

~~Deleted: 30 minutes to 1 hour before first ECP dose; repeat as needed every 4-6 hours~~

~~Deleted: Cyclizine hydrochloride~~

~~Deleted: One 50 mg tablet~~

~~Deleted: 30 minutes before first EC dose;~~

~~Deleted: (Marezine)~~

~~Deleted: repeat as needed every 4-6 hours~~

**Appendix 3 – Title 16, Section 1707.1 of the California Code of Regulations**

**§1707.1. Duty to Maintain Medication Profiles (Patient Medication Records).**

(a) A pharmacy shall maintain medication profiles on all patients who have prescriptions filled in that pharmacy except when the pharmacist has reasonable belief that the patient will not continue to obtain prescription medications from that pharmacy.

(1) A patient medication record shall be maintained in an automated data processing or manual record mode such that the following information is readily retrievable during the pharmacy's normal operating hours.

(A) The patient's full name and address, telephone number, date of birth (or age) and gender;

(B) For each prescription dispensed by the pharmacy:

1. The name, strength, dosage form, route of administration, if other than oral, quantity and directions for use of any drug dispensed;

2. The prescriber's name and where appropriate, license number, DEA registration number or other unique identifier;

3. The date on which a drug was dispensed or refilled;

4. The prescription number for each prescription; and

5. The information required by section 1717.

(C) Any of the following which may relate to drug therapy: patient allergies, idiosyncrasies, current medications and relevant prior medications including nonprescription medications and relevant devices, or medical conditions which are communicated by the patient or the patient's agent.

(D) Any other information which the pharmacist, in his or her professional judgment, deems appropriate.

(2) The patient medication record shall be maintained for at least one year from the date when the last prescription was filled.

Authority cited: Sections 4005, 4121 and 4122, of the Business and Professions Code.

Reference: Sections 4005, 4121 and 4122, of the Business and Professions Code.

Preven was discontinued as of May 2004

Font: Times New Roman, 12 pt

## COMMUNICATION AND PUBLIC EDUCATION COMMITTEE

Goal 4: Provide relevant information to consumers and licensees.

Outcome: Improved consumer awareness and licensee knowledge.

|               |   |
|---------------|---|
| Objective 4.1 | Develop a minimum of 10 communication venues to the public by June 30, 2011.  |
| Measure:      | Number of communication venues developed to the public.   |
| Tasks:        | <ol style="list-style-type: none"> <li data-bbox="367 428 1524 716"> <p>1. <b>Assess the effectiveness of the board's educational materials and outreach: survey consumers to identify whether board-produced materials are valued and what new materials are desired.</b></p> <p><i>2006-2007: Staff conducts assessment of the board's consumer outreach written materials. Material is identified for revision and update, future development, or evaluation for continued need.</i></p> <p><i>2007-2008: Board publishes new board brochure and complaint brochure, and redesigns several board brochures into new single-page, format.</i></p> </li> <li data-bbox="367 716 1524 1493"> <p>2. <b>Restructure the board's website to make it more user friendly.</b></p> <p><i>2006-2007: Website modified to contain lists of disciplinary actions finalized each quarter and permit online access to public documents regarding board disciplinary actions taken against a licensee.</i></p> <p><i>Links added to obtain various information regarding medication safety, and drug interactions, and information from FDA regarding Medications and Medical Devices.</i></p> <p><i>Work Initiated on new website design to meet new state design standards.</i></p> <p><i>2007-2008: New website design completed in November 2007.</i></p> <p><i>Web page created consolidating all information on e-pedigree into one place.</i></p> <p><i>1st Qtr 09/10: Regulation section of the board's Web site updated to improve presentation and readability.</i></p> <p><i>Status of board licensees on probation changed from "active" to "disciplined".</i></p> <p><i>3rd Qtr 09/10: Updated website template to conform with new directive from Governor.</i></p> <p><i>3rd Qtr 10/11: Committee begins project to redesign how board publications are listed on website. Changes to be made when state agencies shift to new website design approved by the Governor's office.</i></p> <p><i>Meeting held with Webmaster, two Board Members, and Executive Officer regarding making the forms/publications page of website more user friendly.</i></p> </li> <li data-bbox="367 1493 1524 1719"> <p>3. <b>Work with the California Health Communication Partnership on integrated public information campaigns on health-care topics.</b></p> <p><i>2006-2007: Committee continues collaboration with the partnership whose fall campaign is screening for prostate and breast cancer. Plans underway to work to promote generic drugs in the future.</i></p> <p><i>No additional meetings scheduled after January 2007.</i></p> </li> </ol> |

**4. Continue collaboration with schools of pharmacy for pharmacist interns to develop consumer fact sheets on health topics.**

**2006-2007:** *Nine previously developed fact sheets are sent to a translation service to develop Spanish, Chinese, and Vietnamese versions of these materials. Four new fact sheets developed and undergoing review by the board.*

**2007-2008:** *The committee determines that the board will expand the project beyond the Center for Consumer Self Care to include students from other Schools of Pharmacy.*

*Meanwhile discussion with UCSF lead to request for funding to continue project.*

*Meanwhile board seeks to establish intern projects with other schools of pharmacy.*

**1st Qtr 08/09:** *Letter to Deans of California's pharmacy schools mailed.*

**1st Qtr 09/10:** *Staff prepare to initiate program using intern coordinators at school of pharmacy campuses in California.*

**4th Qtr 09/10:** *UCSD submits fact sheets for board consideration.*

*Western, USC and California North State all anticipate programs beginning in fall 2010.*

**2nd Qtr 10/11:** *Fact sheets received from UOP and UCSD, additional editing needed.*

**5. Develop a Notice to Consumers to comply with requirements of AB 2583 (Nation, Chapter 487, Statutes of 2006) on patients' rights to secure legitimately prescribed medication from pharmacies.**

**2006-2007:** *Governor signs AB 2583.*

*Committee advances draft regulation text for comment at the October Board Meeting. Board votes to create a second Notice to Consumers poster vs. adding additional language to current poster.*

*Committee refines language to be advanced to the board. Board reviews, modifies, and sets for regulation notice the proposed language for a second Notice to Consumers poster.*

**2007-2008:** *New "Notice to Consumers" approved by board and later by the Office of Administrative Law.*

*New design and layout for two new Notice to Consumer posters are selected.*

**1st Qtr 08/09:** *New posters are mailed to California pharmacies.*

**2nd Qtr 08/09:** *Posters are translated into several languages and made available on the board's website.*

**6. Evaluate the practice of pill splitting as a consumer protection issue.**

**2006-2007:** *Board holds discussion of pill splitting issues during January and April 2007 Board Meetings.*

**2007-2008:** *The Script newsletter contains an article for pharmacists on pill splitting and a Fact Sheet for consumers is completed.*

**7. Evaluate the SCR 49 Medication Errors Report for implementation.**

**2006-2007:** *Communication and Public Education Committee reviews SCR 49 report and board has presentation of the SCR 49 report.*

**2007-2008:** *SB 472 enacted to require the board to standardize container labels into a patient friendly format by 2011.*

**Feb. 2009:** *SB 470 introduced to add "purpose" to the prescription container's label.*

**Sept. 2009:** *SB 470 is enrolled and sent to the Governor.*

- 8. Develop patient-centered standardized prescription container labels by 2011 pursuant to SB 472 (Corbett, Chapter 470, Statutes of 2007).**
- Oct. 2007:** Board president appoints members to subcommittee.
- Jan. 2008:** Board readies plans for six public hearings statewide during 2008
- April 2008:** First meeting in Fremont on April 12. Approximately 40 people attend.
- Apr. - Jul. 08:** Board attends health fairs and interviews patients for information on how to improve prescription labels. Survey available on board's website. 123 surveys completed.
- July 2008:** Board Inspector Bayley and Associate Analysts Durst and Abbe staff a resource table at the Lotus Festival in Los Angeles and interview attendees about their prescription labels as part of the board's initiative to implement a patient-centered prescription label.
- Aug. 2008:** Associate Analysts Durst and Abbe and Assistant Executive Officer Sodergren staff the department's booth at the State Fair and distribute brochures, respond to public questions and elicit suggestions to improve the labeling on prescription labels.
- Oct. 2008:** Board Member Powers provides information and conducted labeling surveys of those attending CARA's annual meeting. Publications Coordinator Abbe attends Celebrando Nuestra Salud to conduct labeling surveys of those in attendance.
- Nov. 2008:** Board sponsors public forum on health literacy and designing patient-centered labels. National experts provide information.
- Dec. 2008:** Board Executive Officer participates on National Association of Boards of Pharmacy task force to develop national standards for patient-centered labels. Board and CPhA develop joint survey for administration via listeners of radio stations on patient medication labels.
- Jan. 2009:** Over 600 consumer surveys submitted; SB 472 Subcommittee meets to begin developing regulations. Radio surveys add 1,800 additional survey responses. Subcommittee holds afternoon meeting in San Diego.
- March 2009:** Evening meeting held on SB 472 task force draws a few more public attendees. Ongoing surveys from consumers continues.
- July 2009:** Draft regulation language discussed by board.
- Aug. 2009:** Draft regulation language discussed by board.
- 2nd Qtr 09/10:** Board holds informational hearing, finalizes language and releases regulation for 45-day comment period.
- Dec. 2009:** Board submits required report to Legislature on implementation to date of SB 472's provisions.
- Jan. 2010:** Board holds regulation hearing and make text changes to be released for 15-day comment period.
- Feb. 2010:** Board meets and deliberates on proposed modified text. Text released for 15-day comment period after meeting from February 22 - March 10, 2010.
- April 2010:** Board meets and discusses the more than 1,200 comments received.
- June 2010:** Board adopts regulation as noticed on February 22, 2010.
- Nov. 2010:** Office of Administrative Law approves regulation.
- Jan. 2011:** Regulation takes effect.

- |  |  |
|--|--|
|  | <p><b>9. Address and promote licensee and public education on minimizing prescription errors.</b></p> <p><i>July 2008:</i> Forum on medication errors held as part of board meeting. Michael Cohen, Institute of Safe Medical Practices, John Keats, California Patient Action Coalition, and Lorian deMartini, California Department of Public Health, talk about activities of their organizations to prevent errors. Board Inspector Orlandella represented the board on a panel to a group of seniors in Roseville, California.</p> <p><i>Jan. 2009:</i> Board publishes medication errors segment in its newsletter, <u>The Script</u>, describing several medication errors investigated by the board.</p> <p><i>June 2009:</i> Enforcement Committee hears presentation on board investigations of medication errors during 2008/2009.</p> <p><i>June 2010:</i> Executive Officer attends meeting, convened by the California Pharmacy Foundation, discussing ways to reduce medication errors in pharmacies.</p> <p><i>April 2011:</i> The Board of Pharmacy and Drug Enforcement Administration host a day-long seminar on Diversion of Controlled Substances "What every pharmacist should know to prevent diversion" in Los Angeles. Executive Officer Herold provides an update on board activities to senior executive members of the Healthcare Distribution Management Association in a Sacramento meeting.</p> <p><b>10. Educate consumers about steps they can take to prevent receiving a medication error.</b></p> <p><i>2nd Qtr 09/10:</i> Develops and distributes 3-minute video tape on how patients can prevent receiving a medication error. Video placed on the board's Website.</p> |
|--|--|

|               |   |
|---------------|---|
| Objective 4.2 | Develop 10 communication venues to licensees by June 30, 2011.  |
| Measure:      | Number of communication venues developed to licensees.  |
| Tasks:        | <ol style="list-style-type: none"> <li data-bbox="370 218 1479 695"> <p>1. Publish <i>The Script</i> two times annually.</p> <p><i>Jul. 2008:</i> <i>The Script</i> published, placed online and mailed to pharmacies and wholesalers.</p> <p><i>Apr. 2009:</i> "February" issue of <i>The Script</i> published, placed online and mailed to pharmacies and wholesalers.</p> <p><i>Jul. 2009:</i> "July" issue of <i>The Script</i> written and undergoing review.</p> <p><i>Jan. 2010:</i> "July" issue of <i>The Script</i>, now finalized.</p> <p><i>March 2010:</i> Titled as "February 2010" board newsletter published and released. Future issues will be released online.</p> <p><i>Sept. 2010:</i> "September" issue released online only; this is the first issue not printed and mailed.</p> <p><i>Feb. 2011:</i> Articles developed and submitted to DCA for review.</p> <p><i>Sept. 2010:</i> "July" issue of <i>The Script</i> released online.</p> </li> <li data-bbox="370 695 1479 1499"> <p>2. Develop board-sponsored continuing education programs in pharmacy law and coordinate presentation at local and annual professional association meetings throughout California.</p> <p><i>2006-2007:</i> The board's members, supervising inspector and executive officer provide 22 CE and licensee educational seminars during the year.</p> <p><i>2007-2008:</i> The board's members, supervising inspector and executive officer provide at least 10 CE and licensee educational seminars during the year.</p> <p><i>1st Qtr 08/09:</i> Board Member Goldenberg provides information about pharmacy law to medical staff at the Jewish Home Hospital in Los Angeles. President Schell speaks on requirements regarding conscience provisions in California law at Loma Linda University.</p> <p><i>2nd Qtr 08/09:</i> Executive Officer Herold speaks to the CSHP's Board of Directors about the board's heparin inspections. Executive Officer Herold speaks to CSHP's Seminar on Board legislative and regulation activities. Assistant Executive Officer Sodergren and Supervising Inspector Ratcliff staff an informational booth at CSHP's Seminar. Executive Officer Herold speaks to CSHP's Seminar on the heparin inspections conducted with the California Department of Public Health in California Hospitals. Executive Officer Herold speaks to CSHP's Seminar on California's e-pedigree requirements.</p> </li> </ol> |

**3rd Qtr 08/09:** Executive Officer Herold and Board President Schell provide three presentations at the California Pharmacists Association's Outlook on the Board of Pharmacy, major issues before the board and medication errors. Supervising Inspector Ratcliff provides a presentation about pharmacy law to 70 students at Loma Linda's School of Pharmacy. President Schell provides a presentation on Board of Pharmacy issues to the San Diego CPhA meeting. Supervising Inspector Ratcliff presents information on "How to Survive a Board Inspection" to 80 pharmacists at a Vietnamese Pharmacist Association. Board President Schell provides a presentation to UCSF School of Pharmacy on ethics and integrity in pharmacy. Executive Officer Herold and President Schell present a 1.5 hour CE lecture on the Board of Pharmacy at that CPhA's annual meeting. Supervising Inspector Ratcliff and Assistant Executive Officer Sodergren staff a booth at the CPhA's annual meeting answering pharmacy law and licensing questions. Executive Officer Herold and President Schell discuss the role of a regulatory agency in investigating and preventing medication errors as CPhA's annual meeting. Executive Officer Herold provides presentation to UCSF and UCSD students in a first year pharmacy school law class. President Schell provides a presentation to students at the USC School of Pharmacy.

**4th Qtr 08/09:** Executive Officer Herold presented information about the Board of Pharmacy and ongoing projects at a California Society of Health-System Pharmacists Town hall meeting at Loma Linda for 80 pharmacists. Executive Officer Herold presented information about the Board of Pharmacy and ongoing projects at a CSHP Town hall meeting at UOP for 60 pharmacists.

**1st Qtr 09/10:** Executive Officer Herold presented at CSHP Board of Directors Meeting. Supervising Inspector Nurse presented at CPhA's Long Term Care Board Meeting. Executive Officer Herold presented at CSHP Sacramento Valley Chapter Meeting.

**3rd Qtr 09/10:** Board inspectors provided five continuing education sessions on pharmacy law or inspections. Additionally the board staffed an information booth at CPhA's annual meeting. Executive Officer Herold provided an update on 2010 pharmacy law changes, and Executive Officer Herold and President Schell provided an update on Board of Pharmacy activities underway and during 2009.

**4thQtr 09/10:** Executive Officer Herold and Supervising Inspector Ratcliff presented information about the Board of Pharmacy and answered questions about pharmacy law to 60 Costco Northern California pharmacy managers.

**1st Qtr 10/11:** Inspector Wong provided information about Board of Pharmacy enforcement activities to students at California Northstate School of Pharmacy.

**2nd Qtr 10/11:** Executive Officer Herold presented information about the 2010 legislative year at Seminar 2010, the annual meeting of the California Society of Health System Pharmacists (CSHP) in San Francisco.  
 Executive Officer Herold and Inspector Hokana staffed the board's public information booth at CSHP's Seminar 2010.  
 Executive Officer Herold presented information on e-prescribing and e-prescribing of controlled drugs to attendees of a CalERx Conference in Oakland.  
 Executive Officer Herold provided a presentation on California's patient-centered prescription container label requirements at a quarterly meeting of the California Hospital Association's Medication Safety Committee.

**3rd Qtr 10/11:** Supervising Inspector Nurse provides information to students at Loma Linda's School of Pharmacy.  
 Supervising Nurse provides training regarding the board's investigations and regulatory jurisdiction at Orange County Med Board and Drug Officer training.  
 Board staffs a booth at CPhA's annual meeting, Outlook.  
 Board President Weisser and Executive Officer Herold provided an update about Board of Pharmacy activities and a Town Hall for questions and answers at Outlook. The two presentations comprised three hours of contact time.  
 Executive Officer Herold provides a presentation on California's e-pedigree requirements via video conference to FDA's Track and Trace Workshop.  
 Executive Officer Herold provides a presentation at a statewide annual meeting of California district and city attorney's offices that handle consumer protection cases about the types of cases investigated by the board including California's serious drug diversion and prescription abuse issues.  
 Executive Officer Herold participates as a trainer in the day-long DCA Board Member Orientation and Training.  
 Supervising Inspector Ratcliff provides training about the board, clinics and Title X in Orange County.  
 Executive Officer Herold provides a presentation about California's identification of the heparin recall failures in 2008 and participates in a two-day workshop hosted by the PEW Trust in Washington DC.  
 Supervising Inspector Ratcliff provides a webinar to Providence Hospital pharmacists.  
 Supervising Inspector Dang gave a presentation on "Surviving as the Pharmacist-in-Charge" at Western University.  
 Inspector Bailey provides information on "How to Survive a Board Inspection" to the Korean Pharmacists Association.

**4th Qtr 10/11:** *Executive Officer Herold provides a presentation to UCSF students about Board of Pharmacy activities.*

*Executive Officer Herold meets with a delegation from Japan regarding California's e-pedigree requirements.*

*The Board of Pharmacy and Drug Enforcement Administration host a day-long seminar on Diversion of Controlled Substances "What every pharmacist should know to prevent diversion" in Los Angeles.*

*Assistant Executive Officer Sodergren provides an update to the CSHP Board of Directors about Board of Pharmacy activities.*

*Executive Officer Herold, Supervising Inspector Nurse and Inspector Sakamura provide information to the consumer law attorneys of Southern California District and City Attorneys about the board's investigations and regulatory jurisdiction.*

*Supervising Inspector Dang provides a CE presentation on new pharmacy laws to over 70 pharmacists at an association meeting in Los Angeles.*

*Executive Officer Herold provides a presentation on California's patient-centered labeling requirements to over 100 individuals at the annual Ralphs manager meeting in Orange County.*

*Executive Officer Herold provides a presentation to over 100 attendees on the board's citation and fine and enforcement programs at the CPhA Celebrate Pharmacy Conference in Oakland. Board Inspector Hunt provides a presentation on responsibilities on how to survive a board inspection and the roles of a PIC at the same conference. New Supervising Inspector Young also provides a presentation on addressing prescription drug abuse.*

*Executive Officer Herold participates in the mandatory DCA day-long training for new board members in Los Angeles on the roles of the executive officer, roles of a board member, and the components of the state enforcement, legislative and budget programs in operation at the boards.*

*Executive Officer Herold provides a Webinar-like presentation at an Axway conference in New Jersey on California's e-pedigree requirements.*

*Executive Officer Herold participates in a conference call of western states' pharmacy board directors hosted by the NABP. This call was initiated at Ms. Herold's request to allow discussion of regulatory issues involving neighboring states.*

*Executive Officer Herold tapes a "postscript blog" with Community Catalyst in Washington DC on the security of the pharmaceutical supply chain and the issues identified in California surrounding the 2008 heparin recalls. This is part of the PEW Trust's forthcoming report on the 2008 heparin contamination which affected the supply of heparin in the US.*

**3. Maintain important and timely licensee information on website.**

**2006-2007:** *Added 50-year pharmacist recognition pages as a special feature.  
Updated license totals.  
Added enforcement actions for effective dates between April 1 and June 30, 2005.  
Changed definitions on license lookup to clarify license status.  
Sent out more than 50 subscriber alert notifications to the board's e-mail notification list.  
Unveiled new website of the board, and created new web links.  
Revised and added new fax and contact information to speed communication with appropriate enforcement and licensing staff.  
Added frequently asked questions on emerging contraception.  
Updated the board's online lawbook.  
Created a page dedicated to drug alerts and recalls.  
Sent out three disaster response subscriber alerts regarding the Southern California wildfires to the board's e-mail notification list.  
Created a page dedicated to e-pedigree information and laws.  
Updated the 2008 lawbook.  
Added two sets of comments submitted to the FDA in support of a unique identifier and on promising technologies for prescription drug identification, validation, track and trace or authentication to e-pedigree page.  
Added survey of patients for prescription container labels.  
Added page for subscription to board mailing list.*

**1st Qtr 08/09:** *Updated information regarding release of exam results.  
Added enforcement actions for the effective dates between July 1 and September 30, 2008.  
Added two recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 24 subscriber alert notifications to the board's email notification list.*

**2nd Qtr 08/09:** *Updated online renewal forms for individual licenses.  
Created information on CURES page.  
Created a survey page for public opinion on how to improve prescription labels (SB 472) in English and Spanish.  
Added three recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 20 subscriber alert notifications to the board's email notification list.*

**3rd Qtr 08/09:** *Began process of making all PDFs on board's website accessible for the visually impaired.  
Added four recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 27 subscriber alert notifications to the board's email notification list.  
Posted latest edition of The Script.  
Board mails letter pursuant to SJR 19 (Ridley-Thomas, Statutes of 2008) regarding prohibition of healing arts licensees not to engage in torture.*

- 4th Qtr 08/09:** *Continued making all PDFs on board's website accessible for the visually impaired.  
Updated lawbook to 2009 edition.  
Added four recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 26 subscriber alert notifications to the board's email notification list.*
- 1st Qtr 09/10:** *Updated information regarding release of exam results.  
Added enforcement actions and accusations for the effective dates between July 1 and September 30, 2009.  
Made Pending Regulations page more user friendly.  
Posted board and committee meeting agendas and materials.  
Sent out 16 subscriber alert notifications to the board's email notification list.*
- 2nd Qtr 09/10:** *Added enforcement actions and accusations for the effective dates between Oct 1 through Dec 31, 2009.  
Posted board and committee agendas and materials.  
Sent out 28 subscriber alert notifications to the Board's email subscriber list.  
Migrated subscriber list to new software program and created an additional subscriber list for emergency compounding.*
- 3rd Qtr 09/10:** *Added enforcement actions and accusations for the effective dates between January 1 through March 31, 2010.  
Updated lawbook to 2009 edition.  
Posted board and committee agendas and materials.  
Sent out 17 subscriber alert notifications to the Board's email subscriber list.  
Created online Change of Address form.*
- 4th Qtr 09/10:** *Added enforcement actions and accusations for the effective dates between April 1 through June 30, 2010.  
Posted board and committee agendas and materials.  
Sent out 16 subscriber alert notifications to the Board's email subscriber list.*
- 1st Qtr 10/11:** *Added enforcement actions and accusations for the effective dates between July 1 and September 30, 2010.  
Updated information regarding release of exam results.  
Continued making all PDFs on board's website accessible for the visually impaired.  
Updated lawbook to 2010 edition.  
Added 2 recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 24 subscriber alert notifications to the board's email notification list.  
Posted latest edition of The Script.*
- 2nd Qtr 10/11:** *Added enforcement actions and accusations for the effective dates between October 1 and December 31, 2010.  
Updated information regarding release of exam results.  
Continued making all PDFs on board's website accessible for the visually impaired.  
Added 30 recall notifications to FDA recall page.  
Posted board and committee meeting agendas and materials.  
Sent out 53 subscriber alert notifications to the board's email notification list.*

|  |  |
|--|--|
|  | <p><b>3rd Qtr 10/11:</b> <i>Added enforcement actions and accusations for the effective dates between January 1 and Marcy 31, 2011.</i><br/><i>Updated information regarding release of exam results.</i><br/><i>Continued making all PDFs on board's website accessible for the visually impaired.</i><br/><i>Posted board and committee meeting agendas and materials.</i><br/><i>Sent out 78 subscriber alert notifications, of which 67 were recall notices, to the board's email notification list.</i></p> <p><b>4th Qtr 10/11:</b> <i>Added enforcement actions and accusations for the effective dates between April 1 and June 30, 2011.</i><br/><i>Updated information regarding release of exam results.</i><br/><i>Continued making all PDFs on board's website accessible for the visually impaired.</i><br/><i>Posted board and committee meeting agendas and materials.</i><br/><i>Sent out 51 subscriber alert notifications, of which 28 were recall notices, to the board's email notification list.</i></p> |
|--|--|

|               |   |
|---------------|---|
| Objective 4.3 | Develop communication venues for other health care professionals (e.g., physicians, nurses).  |
| Measure:      | Number of communication venues developed to other health care professionals.  |
| Tasks:        | <i>2nd Qtr 10/11: Worked with Medical Board to produce guidance document for pharmacies and prescribers on the DEA's requirements for e-prescribing controlled drugs.</i> |
|               |   |

|               |   |
|---------------|---|
| Objective 4.4 | Participate in 12 forums, conferences and public education events annually.   |
| Measure:      | Number of forums participated.  |
| Tasks:        | <p>1. <b>Participate in forums, conferences and educational fairs.</b></p> <p><b>1st Qtr 09/10:</b> Board President Schell volunteers in "Standdown" an event for homeless veterans in San Diego and dispensed prescriptions and counseled patient's regarding their medications.<br/> Executive Officer Herold makes a presentation on patient-centered medication labels during a "Women in Government Conference" in San Diego. The group was comprised of female legislators representing the western United States.<br/> Board President Schell makes a presentation to the Indian Pharmacist Association about board activities.<br/> Supervising Inspector Nurse makes a presentation to the California Pharmacists Associations Long Term Care Board regarding DEA and CURES compliance issues.<br/> Executive Officer Herold makes a presentation on California e-pedigree requirements to Logipharma to a group of manufacturers.<br/> Executive Officer Herold makes a presentation on California e-pedigree requirements to Specialty Pharma to a group of contract drug manufacturers.</p> <p><b>2nd Qtr 09/10:</b> Executive Officer Herold presents information on e-pedigree requirements to Healthcare Distributors Management Association's Track and Trace Conference.<br/> Executive Officer Herold provides CE presentation on medication errors as part of a day long conference at California Northstate College of Pharmacy.<br/> Executive Officer Herold provides a presentation on "take back" drugs to 20 rural California County Governments.<br/> Executive Officer Herold provides CE presentation on activities of the board the Sacramento Valley Society of Health Systems Pharmacists.<br/> Supervising Inspector Dang provides a CE presentation to a group of pharmacists in Orange County.<br/> Executive Officer Herold provides information about the board's patient-centered label requirements to CPhA's Long Term Care Committee.<br/> Executive Officer Herold and President Schell attended California Hospital Association's Hospital Drug Distribution Meeting in Sacramento.</p> |

**3rd Qtr 09/10:** Executive Officer Herold did a Webinar on California's e-pedigree requirements hosted by IBS.  
Executive Officer Herold and Assistant Executive Officer Sodergren did a presentation to 200 California NorthState School of Pharmacy students on the board's enforcement program.  
Supervising Inspector Nurse provided information to 50 consumers about medication discount plans, Internet purchase of drugs, counterfeit drugs and obtaining medication safety.  
President Schell provided information at UCSF about pharmacy at Career Day.  
Supervising Inspector Nurse provided a presentation on pharmacy law to Loma Linda students.  
President Schell provided a presentation on the future of pharmacy to 200 students at CAL.

**4th Qtr 09/10:** Executive Officer Herold presented information about the Board of Pharmacy and ongoing projects at a California Society of Health-System Pharmacists Board of Directors Meeting in Sacramento.  
Executive Officer Herold and Supervising Inspector Ratcliff presented information about the Board of Pharmacy and answered questions about pharmacy law to 60 Costco Northern California pharmacy managers.  
Board Member Kajioka provided presentations to students at the University of the Pacific about new pharmacy law and projects at the Board of Pharmacy.  
Supervising Inspector Nurse made a presentation about drug thefts and robberies from pharmacies at a day-long San Diego Pharmacy Conference hosted by the federal Drug Enforcement Administration. Over 100 pharmacy representatives attended.  
Board President Schell and Executive Officer Herold hosted a booth at the annual National Association of Boards of Pharmacy Meeting in Orange County.  
Inspector Toevs provided a presentation about lowering drug costs at a community meeting hosted by Senator Liu in Los Angeles  
Executive Officer Herold presented information about the board's compounding requirements and other key board issues to a meeting of the Bay Area Pharmacy Directors at Stanford.  
Executive Officer Herold attended a conference hosted by the California Endowment on Building Quality and Equitable Health Care Systems in Los Angeles.  
Board Member Schell and Executive Officer Herold participated in a High Risk Drug Task Force Meeting, hosted by the California Hospital Association.  
Executive Officer Herold attended a Medication Safe Alliance Conference in San Francisco hosted by the Pharmacy Foundation of California.  
Executive Officer Herold presented information on the role of the executive officer at the Department of Consumer Affairs Board Member Orientation in Sacramento.

**1st Qtr 10/11:** *Executive Officer Herold presented information about preventing medication errors, the Board of Pharmacy's mandate and ongoing projects at a DCA-hosted meeting of consumers in Sacramento. The FDA also provided information during event.*

*Executive Officer Herold provided information about the CIWMB's drug take back guidelines at a CalRecycle Hearing focusing on a draft report to the Legislature (the board also submitted written comments following this hearing).*

*Executive Officer Herold provided comments on a hospital repopulation policy developed by the California Hospital Association with the Department of Public Health via conference call. (This document was finalized in October.)*

*Executive Officer Herold provided information about the board's ongoing activities at the NACDs Technology Meeting in San Diego.*

*Executive Officer Herold attended an invitation only conference at UCSF on pharmacy leadership, which focused on inpatient facilities.*

*President Weisser and Board Member Veale hosted a board information booth at the Indian Pharmacist Annual Meeting in Orange County.*

*Executive Officer Herold provided a presentation to 300 attendees on California's e-pedigree requirements to pharmaceutical company compliance staff at the 2010 PDMA Sharing Conference in San Diego.*

*Executive Officer Herold participated as a member of the National Association of Pharmacy Board's Task Force on Recommended Revisions to the federal Controlled Substances Act. Participation was via telephone call because out of state travel would have been required to physically attend the meeting.*

*Executive Officer Herold and Board Liaison Joshua Room provided information about California's e-pedigree requirements at the GS1 workshop conference in San Francisco.*

*Executive Officer Herold presented information about preventing medication errors, the Board of Pharmacy's mandate and ongoing projects at a DCA-hosted meeting of consumers in Sacramento. The FDA also provided information during event.*

*Executive Officer Herold provided information about the CIWMB's drug take back guidelines at a CalRecycle Hearing focusing on a draft report to the Legislature (the board also submitted written comments following this hearing).*

*Executive Officer Herold provided comments on a hospital repopulation policy developed by the California Hospital Association with the Department of Public Health via conference call. (This document was finalized in October.)*

*Executive Officer Herold provided information about the board's ongoing activities at the NACDs Technology Meeting in San Diego.*

*Executive Officer Herold provided information about the board's Intern Fact Sheet Project to students at the University of the Pacific who are working on fact sheets for the board.*

|  |   |
|--|---|
|  | <p><b>2nd Qtr 10/11:</b> Board Vice President Kajioka provided information about the board's consumer materials to a group of 150 consumers at a consumer education event in Assemblymember Hayashi's district.</p> <p>Executive Officer Herold attended an invitation only conference at UCSF on pharmacy leadership, which focused on inpatient facilities.</p> <p>President Weisser and Board Member Veale hosted a board information booth at the Indian Pharmacist Annual Meeting in Orange County.</p> <p><b>3rd Qtr 10/11:</b> Executive Officer Herold provides a presentation on California's e-pedigree requirements via video conference to FDA's Track and Trace Workshop. DEA and board cohost day-long conference for pharmacies of controlled substances. Due to interest and success, more conferences planned.</p> <p>Executive Officer Herold provides a presentation about California's identification of the heparin recall failures in 2008 and participates in a two-day workshop hosted by the PEW Trust in Washington DC.</p> |
|--|---|